The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and significant returns is clear, the connected risks are also considerable. M… Read More